Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 9, 2008, Pages 2985-2989

  Ruel, Réjean ^a   Thibeault, Carl ^a   L'Heureux, Alexandre ^a   Martel, Alain ^a   Cai, Zhen Wei ^a   Wei, Donna ^a   Qian, Ligang ^a   Barrish, Joel C ^a   Mathur, Arvind ^a   D'Arienzo, Celia ^a   Hunt, John T ^a   Kamath, Amrita ^a   Marathe, Punit ^a   Zhang, Yueping ^a   Derbin, George ^a   Wautlet, Barri ^a   Mortillo, Steven ^a   Jeyaseelan Sr , Robert ^a   Henley, Benjamin ^a   Tejwani, Ravindra ^a   Bhide, Rajeev S ^a   Trainor, George L ^a   Fargnoli, Joseph ^a   Lombardo, Louis J ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiogenesis; Inhibitors; Kinase; Pyrrolotriazine; VEGFR 2

Indexed keywords

5 ISOPROPYL 6 (5 METHYL 1,3,4 OXADIAZOL 2 YL) N (2 METHYL 1H PYRROLO[2,3 B]PYRIDIN 5 YL)PYRROLO[2,1 F][1,2,4]TRIAZIN 4 AMINE; BMS 540215; BMS 645737; PROTEIN TYROSINE KINASE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CYTOCHROME P-450 CYP3A; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; PROTEIN-TYROSINE KINASES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42949111686     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.03.057     Document Type: Article

References (18)

1. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., and De Bruijn E.A. Pharmacol. Rev. 56 (2004) 549
2. Shawver L.K., Lipson K.E., Fong T.A.T., McMahon G., Plowman G.D., and Strawn L.M. Drug Discov. Today 2 (1997) 50
3. Carmeliet P., and Jain R.K. Nature 407 (2000) 249
4. Zakarija A., and Soft G. Curr. Opin. Oncol. 17 (2005) 578
5. Traxler P. Expert Opin. Ther. Targets 7 (2003) 215
6. Traxler P. Exp. Opin. Investig. Drugs 11 (2002) 1447
7. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., Smith N.R., James N.H., Dukes M., Curwen J.O., Chester R., Jackson J.A., Boffey S.J., Kilburn L.L., Barnett S., Richmond G.H.P., Wadsworth P.F., Walker M., Bigley A.L., Taylor S.T., Cooper L., Beck S., Jurgensmeier J.M., and Ogilvie D.J. Cancer Res. 65 (2005) 4389
8. Gingrich D.E., Reddy D.R., Iqbal M.A., Singh J., Aimone L.D., Angeles T.S., Albom M., Yang S., Ator M.A., Meyer S.L., Robinson C., Ruggeri B.A., Dionne C.A., Vaught J.L., Mallamo J.P., and Hudkins R.L. J. Med. Chem. 46 (2003) 5375
9. Beebe J.S., Jani J.P., Knauth E., Goodwin P., Higdon C., Rossi A.M., Emerson E., Finkelstein M., Floyd E., Harriman S., Atherton J., Hillerman S., Soderstrom C., Kou K., Gant T., Noe M.C., Foster B., Rastinejad F., Marx M.A., Schaeffer T., Whalen P.M., and Roberts W.G. Cancer Res. 63 (2003) 7301
10. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
11. Abrams T.J., Murray L.J., Pesenti E., Walker Holway V., Colombo T., Lee L.B., Cherrington J.M., and Pryer N.K. Mol. Cancer Ther. 2 (2003) 1011
12. Bhide R.S., Cai Z.-W., Zhang Y.-Z., Qian L., Wei D., Barbosa S., Lombardo L.J., Borzilleri R.M., Zheng X., Wu L.I., Barrish J.C., Kim S.-H., Leavitt K., Mathur A., Leith L., Chao S., Wautlet B., Morillo S., Jeyaseelan R., Kukral D., Hunt J.T., Kamath A., Furra A., Vyas V., Marathe P., D'Arienzo C., Derbin G., and Fargnoli J. J. Med. Chem. 49 (2006) 2143
13. Cai Z.-W., Zhang Y., Borzilleri R.M., Qian L., Barbosa S., Wei D., Zheng X., Wu L., Fan J., Shi Z., Wautlet B., Mortillo S., Jeyaseelan R., Kukral D.W., Kamath A., Marathe P., D'Arienzo C., Derbin G., Barrish J.C., Robl J.A., Hunt J.T., Lombardo L.J., Fargnoli J., and Bhide R.S. J. Med. Chem. 51 (2008) 1976
14. Borzilleri R.M., Zheng X., Qian L., Ellis C., Cai Z.-W., Wautlet B., Mortillo S., Jeyaseelan R., Kukral D.W., Fura A., Kamath A., Vyas V., Tokarski J.S., Barrish J.C., Hunt J.T., Lombardo L.J., Fargnoli J., and Bhide R.S. J. Med. Chem. 48 (2005) 3991
15. Borzilleri R.M., Fargnoli J., Fura A., Gerhardt T., Goyal B., Hunt J.T., Mortillo S., Qian L., Tokarski J., Vyas V., Wautlet B., Zheng X., and Bhide R.S. Bioorg. Med. Chem. 15 (2005) 1429
16. For the assay conditions of in vitro kinase, cellular proliferation, metabolic stability, cytochrome P450 and pharmacokinetics, see Ref. 5a. See Supporting information for hERG assay conditions.
17. The coupling reactions yielding other analogs disclosed in Tables 1 and 2 proceeded similarly using alternate syntheses of chloroimidates (see Refs.5a and 5b) and azaindoles (see Refs.7a and 7b):. Thibault C., L'Heureux A., Bhide R.S., and Ruel R. Org. Lett. 5 (2003) 5023
18. L'Heureux A., Thibault C., and Ruel R. Tetrahedron Lett. 45 (2004) 2317